Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 18, 2008, Pages 5134-5139

  Pinard, Emmanuel ^a   Alberati, Daniela ^a   Borroni, Edilio ^a   Fischer, Holger ^a   Hainzl, Dominik ^a   Jolidon, Synèse ^a   Moreau, Jean Luc ^a   Narquizian, Robert ^a   Nettekoven, Matthias ^a   Norcross, Roger D ^a   Stalder, Henri ^a   Thomas, Andrew W ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Benzoylpiperazine; Glycine; GlyT1; Inhibitor; NMDA; Schizophrenia; Transporter

Indexed keywords

2 CHLORO N [ALPHA (2 PIPERIDINYL)BENZYL] 3 TRIFLUOROMETHYLBENZAMIDE; ALX 5407; BENZOYLPIPERAZINE DERIVATIVE; GLYCINE TRANSPORTER 1; LU AA 20465; ORG 25935; PIPERAZINE DERIVATIVE; SARCOSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; BENZOIC ACIDS; BRAIN; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; MOLECULAR STRUCTURE; PIPERAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 51349102049     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.07.086     Document Type: Article

References (29)

1. For a recent review, see. Javitt D.C. Int. Rev. Neurobiol. 78 (2007) 69
2. Danysz W., and Parsons C.G. Pharmacol. Rev. 50 (1998) 597
3. Sur C., and Kinney G.G. Curr. Drug Targets 8 (2007) 643
4. Thomsen C. Drug Discov. Today 3 (2006) 539
5. Shim S.S., Hammonds M.D., and Kee B.S. Eur. Arch. Psychiatry Clin. Neurosci. 258 (2008) 16
6. For recent reviews, see. Hashimoto K. Central Nervous Syst. Agents Med. Chem. 7 (2007) 177
7. Harsing L.G., Juranyi Z., Gacsalyi I., Tapolcsanyi P., Czompa A., and Matyus P. Curr. Med. Chem. 13 (2006) 1017
8. Lindsley C.W., Wolkenberg S.E., and Kinney G.G. Curr. Top. Med. Chem. 6 (2006) 1883
9. Atkinson B.N., Bell S.C., De Vivo M., Kowalski L.R., Lechner S.M., Ognyanov V.I., Tham C.-S., Tsai C., Jia J., Ashton D., and Klitenick M.A. Mol. Pharmacol. 60 (2001) 1414
10. Gibson, S. G.; Jaap, D. R.; Thorn, S. N.; Gilfillan, R. WO Patent 2000007978, 2000; Chem. Abstr. 2000, 132, 166509.
11. Smith G., Ruhland T., Mikkelsen G., Andersen K., Christoffersen C.T., Alifrangis L.H., Mork A., Wren S.P., Harris N., Wyman B.M., and Brandt G. Bioorg. Med. Chem. Lett. 14 (2004) 4027
12. Dargazanli, G.; Estenne Bouhtou, G.; Magat, P.; Marabout, B.; Medaisko, F.; Roger, P.; Sevrin, M.; Veronique, C. FR 2838739, 2003; Chem. Abstr. 2003, 139, 337891.
13. Zhao Z., O'Brien J.A., Lemaire W., Williams D.L., Jacobson M.A., Sur C., Pettibone D.J., Tiller P.R., Smith S., Hartman G.D., Wolkenberg S.E., and Lindsley C.W. Bioorg. Med. Chem. Lett. 16 (2006) 5968
14. Pinard E., Ceccarelli S.M., Stalder H., and Alberati D. Bioorg. Med. Chem. Lett. 16 (2006) 349
15. Ceccarelli S.M., Pinard E., Stalder H., and Alberati D. Bioorg. Med. Chem. Lett. 16 (2006) 354
16. Alberati D., Ceccarelli S.M., Jolidon S., Krafft E.A., Kurt A., Maier A., Pinard E., Stalder H., Studer D., Thomas A.W., and Zimmerli D. Bioorg. Med. Chem. Lett. 16 (2006) 4305
17. Alberati D., Hainzl D., Jolidon S., Krafft E.A., Kurt A., Maier A., Pinard E., Thomas A.W., and Zimmerli D. Bioorg. Med. Chem. Lett. 16 (2006) 4311
18. Alberati D., Hainzl D., Jolidon S., Kurt A., Pinard E., Thomas A.W., and Zimmerli D. Bioorg. Med. Chem. Lett. 16 (2006) 4321
19. Pinard, E.; Alberati, D.; Borroni, E.; Ceccarelli, S. M.; Fischer, H.; Hainzl, D.; Jolidon, S.; Moreau, J. L.; Stalder, H.; Thomas, A. W. Abstracts of Papers, 231st ACS National Meeting, Atlanta, GA, United States, March 26-30, 2006; MEDI-407.
20. Nettekoven M., and Thomas A.W. Curr. Med. Chem. 9 (2002) 2179
21. +).
22. 50 of 26 nM.
23. 3H]-glycine: 200 nM, cold glycine not present.
24. For a review, see. Purohit V., and Basu A.K. Chem. Res. Toxicol. 13 (2000) 673
25. Kansy M., Senner F., and Gubernator K. J. Med. Chem. 41 (1998) 1007
26. Compound initially in DMSO solution is lyophilized, then dissolved in 0.05 M phosphate buffer (pH 6.5), stirred for 1 h, and shaken for 2 h. After one night, the solution is filtered and the filtrate is analyzed by direct UV measurement or by HPLC-UV.
27. Gerber Molecular Design, Amden, Switzerland, http://www.moloc.ch.
28. The panel consisted in targets included in the standard CEREP high throughput profile screen complemented with enzymes (phosphodiesterases, kinases, MAO-A, COMT, acetylcholineesterase). http://www.cerep.fr.
29. Möller C., and Netzer R. Eur. J. Pharm. 532 (2006) 44